Robert Dolski
Director Financiero/CFO en AUTOLUS THERAPEUTICS PLC .
Cargos activos de Robert Dolski
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AUTOLUS THERAPEUTICS PLC | Director Financiero/CFO | 07/08/2023 | - |
Historial de carrera de Robert Dolski
Antiguos cargos conocidos de Robert Dolski.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
AKCEA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 24/04/2020 | 18/05/2020 |
Director Financiero/CFO | 24/04/2020 | 18/05/2020 | |
Corporate Officer/Principal | 01/05/2019 | 24/04/2020 | |
MODERNA, INC. | Corporate Officer/Principal | 01/06/2016 | 01/05/2019 |
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Corporate Officer/Principal | 01/12/2013 | 01/06/2016 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01/04/2007 | 01/12/2012 |
CHECKMATE PHARMACEUTICALS, INC. | Director Financiero/CFO | 04/01/2021 | - |
Contacto de Relaciones con Inversores | 04/01/2021 | - |
Formación de Robert Dolski.
University of Pennsylvania | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 8 |
Reino Unido | 2 |
Operativa
Corporate Officer/Principal | 4 |
Director of Finance/CFO | 3 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 7 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
MODERNA, INC. | Health Technology |
AUTOLUS THERAPEUTICS PLC | Health Technology |
Empresas privadas | 4 |
---|---|
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
FORUM Pharmaceuticals, Inc.
FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Robert Dolski
- Experiencia